20. Andresen M, Boyd N (2008) A cost-benefit and cost-effectiveness analysis of Vancouver’s Safe Injection Facility. Vancouver, British Columbia. 21. Wood E, Tyndall MW, Qui Z, Zhang R, Montaner JS, et al. (2006) Service uptake and characteristics of injection drug users utilizing North America’s first medically supervised safer injecting facility. American journal of public health 96: 770–773. 22. Wood E, Stoltz JA, Li K, Montaner JS, Kerr T (2006) Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction 101: 689–695. 23. Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, et al. (2007) Identifying injection drug users at risk of nonfatal overdose. Academic emergency medicine 14: 616–623. 24. Kerr T, Fairbairn N, Tyndall MW, Marsh D, Li K, et al. (2007) Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug and alcohol dependence 87: 39–45. 25. Darke S, Williamson A, Ross J, Mills KL, Havard A, et al. (2007) Patterns of nonfatal heroin overdose over a 3-year period: findings from the Australian treatment outcome study. J Urban Health 84: 283–291. 26. Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, et al. (2007) Release from prison–a high risk of death for former inmates. The New England journal of medicine 356: 157–165. 27. (2007) News release: Insite given six-month extension says Minister Clement. In: Canada H, ed. Ottawa, Ontario, Canada: Government of Canada. 28. (2008) Evidence, Thursday, May 29, 2008. Ottawa, Ontario, Canada: Standing Committee on Health, Parliament of Canada. 29. Remis R, Leclerc P, Routledge R, Taylor C, Bruneau J, et al. (1998) Consortium to characterize injection drug users in Canada (Montreal, Toronto and Vancouver). Toronto, Ontario: Department of Public Health Sciences, University of Toronto. 30. Schechter MT, O’Shaughnessy MV (1999) Guesstimating the number of injection drug users in the Lower Mainland: A brief report. Vancouver, British Columbia: Centre for Evaluation & Outcome Sciences/British Columbia Centre for Excellence in HIV/AIDS. 31. Darke S, Mattick RP, Degenhardt L (2003) The ratio of non-fatal to fatal heroin overdose. Addiction 98: 1169–1171. 32. Wood RA, Wood E, Lai C, Tyndall M, Montaner J, et al. (2008) Nurse- delivered safer injection education among a cohort of injection drug users: Evidence from the evaluation of Vancouver’s supervised injection facility International Journal of Drug Policy ePub ahead of press. 33. Kerr T, Small W, Moore D, Wood E (2007) A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver’s safer injection facility. Interna- tional Journal of Drug Policy 18: 37–45. OD Deaths Averted in SIF 34. Montaner JS, Hogg RS, Weber AE, Anis AH, O’Shaughnessy MV, et al. (1998) The costs of triple-drug anti-HIV therapy for adults in the Americas. JAMA 279: 1263–1264. 35. Wood E, Schechter MT, Tyndall MW, Montaner JS, O’Shaughnessy MV, et al. (2000) Antiretroviral medication use among injection drug users: two potential futures. AIDS 14: 1229–1235. 36. (1999) Annual Report 1998. Victoria, British Columbia, Canada: British Columbia Vital Statistics Agency. 37. (2000) Annual Report 1999. Victoria, British Columbia, Canada: British Columbia Vital Statistics Agency. 38. (2001) Annual Report 2000. Victoria, British Columbia, Canada: British Columbia Vital Statistics Agency. 39. (2002) Annual Report 2001. Victoria, British Columbia, Canada: British Columbia Vital Statistics Agency. 40. (2003) Annual Report 2002. Victoria, British Columbia, Canada: British Columbia Vital Statistics Agency. 41. (2004) Annual Report 2003. Victoria, British Columbia, Canada: British Columbia Vital Statistics Agency. 42. (2005) Annual Report 2004. Victoria, British Columbia, Canada: British Columbia Vital Statistics Agency. 43. (2006) Annual Report 2005. Victoria, British Columbia, Canada: British Columbia Vital Statistics Agency. 44. (2007) Annual Report 2006. Victoria, British Columbia, Canada: British Columbia Vital Statistics Agency. 45. Bennett GA, Higgins DS (1999) Accidental overdose among injecting drug users in Dorset, UK. Addiction. 46. Darke S, Hall W (2003) Heroin overdose: research and evidence-based intervention. Journal of urban health 80: 189–200. 47. Darke S, Williamson A, Ross J, Teesson M (2005) Non-fatal heroin overdose, treatment exposure and client characteristics: findings from the Australian treatment outcome study (ATOS). Drug and alcohol review 24: 425–432. 48. Gossop M, Griffiths P, Powis B, Williamson S, Strang J (1996) Frequency of non- fatal heroin overdose: survey of heroin users recruited in non-clinical settings. BMJ 313: 402. 49. McGregor C, Darke S, Ali R, Christie P (1998) Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. Addiction 93: 701–711. 50. Ochoa KC, Davidson PJ, Evans JL, Hahn JA, Page-Shafer K, et al. (2005) Heroin overdose among young injection drug users in San Francisco. Drug and alcohol dependence 80: 297–302. 51. Vingoe L, Welch S, Farrell M, Strang J (1999) Heroin overdose among a treatment sample of injecting drug misusers: accident or suicidal behaviour? Journal of Substance Use 4: 88–91. 52. Warner-Smith M, Darke S, Day C (2002) Morbidity associated with non-fatal heroin overdose. Addiction 97: 963–967. PLoS ONE | www.plosone.org 6 October 2008 | Volume 3 | Issue 10 | e3351